Preparation and physicochemical characterization of a novel paclitaxel-loaded amphiphilic aminocalixarene nanoparticle platform for anticancer chemotherapy

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 10, 2012, Pages 1403-1411

  Weeden, Clare ^a   Hartlieb, Karel J ^a   Lim, Lee Yong ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

aminocalixarene; nanoparticle; paclitaxel

Indexed keywords

CALIXARENE; NANOCARRIER; PACLITAXEL; POLYVINYL ALCOHOL; TETRAHEXYLOXY TETRA PARA AMINOCALIX[4]ARENE; UNCLASSIFIED DRUG;

AGGLOMERATION; ARTICLE; CHEMICAL PHENOMENA; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG PURITY; DRUG RELEASE; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NANOENCAPSULATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PROTON NUCLEAR MAGNETIC RESONANCE; SURFACE PROPERTY; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ALBUMINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CALIXARENES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EXCIPIENTS; HYDROGEN-ION CONCENTRATION; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; POLYVINYL ALCOHOL; SERUM ALBUMIN, BOVINE; TIME FACTORS;

EID: 84865866417     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01518.x     Document Type: Article

References (45)

1. Wright AJ, et al,. Novel resorcin[4]arenes as potassium-selective ion-channel and transporter mimics. Chem Eur J 2001; 7: 3474-3481. (Pubitemid 32802513)
2. Sansone F, et al,. Calixarenes in bioorganic and biomimetic chemistry. In:, Asfari Z, et al., eds. Calixarenes. New York: Kluwer Academic Publishers, 2002: 496-512.
3. Bagnacani V, et al,. Macrocyclic nonviral vectors: high cell transfection efficiency and low toxicity in a lower rim guanidinium calix[4]arene. Org Lett 2008; 10: 3953-3956.
4. Park HS, et al,. Modulation of protein-protein interactions by synthetic receptors: design of molecules that disrupt serine protease-proteinaceous inhibitor interaction. Proc Natl Acad Sci U S A 2002; 99: 5105-5109. (Pubitemid 34411510)
5. Colston MJ, et al,. Antimycobacterial calixarenes enhance innate defense mechanisms in murine macrophages and induce control of Mycobacterium tuberculosis infection in mice. Infect Immun 2004; 72: 6318-6323. (Pubitemid 39425411)
6. Mourer M, et al,. Functional organisation and gain of activity: The case of the antibacterial tetra-para-guanidinoethyl-calix[4]arene. Bioorg Med Chem Lett 2006; 16: 2960-2963.
7. Hwang KM, et al,. Antithrombotic treatment with calix-[n]-arene compounds. US Patent 5,409,959, 1995.
8. Harris SJ,. Preparation of calixarene-based compounds having antibacterial, antifungal, anticancer, and anti-HIV activity. PCT Int. Appl. WO 9519974, 1995.
9. Gutsche CD, ed. Calixarenes: An Introduction, 2nd edn. Cambridge: Royal Society of Chemistry, 2008.
10. Krause-Heuer AM, et al,. Substituted β-cyclodextrin and calix[4]arene as encapsulatory vehicles for platinum(II)-based DNA intercalators. Inorg Chem 2008; 47: 6880-6888.
11. Millership JS,. A preliminary investigation of the solution complexation of 4-sulphonic calix[n]arenes with testosterone. J Incl Phenom Macro 2001; 39: 327-331. (Pubitemid 33654917)
12. Yang W, de Villiers MM,. Effect of 4-sulphonato-calix[n]arenes and cyclodextrins on the solubilization of niclosamide, a poorly water soluble anthelmintic. AAPS J 2005; 7: 241-248.
13. Yang W, et al,. Effect of para-sulfonato-calix[n]arenes on the solubility, chemical stability, and bioavailability of a water insoluble drug nifedipine. Curr Drug Discov Technol 2008; 5: 129-139. (Pubitemid 351883826)
14. Shahgaldian P, et al,. Para-acyl calix[4]arenes: amphiphilic self-assembly from the molecular to the mesoscopic level. Chem Commun 2002; 4: 326-327. (Pubitemid 34177710)
15. Bize C, et al,. Spontaneous formation of vesicles in a catanionic association involving a head and tail functionalized amino-calix[6]arene. Chem Commun 2010; 46: 586-588.
16. Manfredi JJ, et al,. Taxol binds to cellular microtubules. J Cell Biol 1982; 94: 688-696.
17. Kloover JS, et al,. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 2004; 90: 304-305. (Pubitemid 38250619)
18. Song D, et al,. Binding of taxol to plastic and glass containers and protein under in vitro conditions. J Pharm Sci 1996; 85: 29-31. (Pubitemid 26029067)
19. mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene 1998; 16: 2087-2094. (Pubitemid 28211683)
20. Micha JP, et al,. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions. Gynecol Oncol 2006; 100: 437-438. (Pubitemid 43075284)
21. Sparreboom A, et al,. Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 2005; 11: 4136-4143. (Pubitemid 40791578)
22. Maeda H,. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001; 41: 189-207.
23. Dhanikula AB, Panchagnula R,. Localized paclitaxel delivery. Int J Pharm 1999; 183: 85-100. (Pubitemid 29257954)
24. Shen SI, et al,. Synthesis and characterization of RGD-fatty acid amphiphilic micelles as targeted delivery carriers for anticancer agents. J Drug Target 2007; 15: 51-58.
25. Crosasso P, et al,. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J Control Release 2000; 63: 19-30. (Pubitemid 30046939)
26. Mo Y, Lim L,. Preparation and in vitro anticancer activity of wheat germ agglutinin (WGA)-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate. J Control Release 2005; 107: 30-42. (Pubitemid 41253700)
27. Shahgaldian P, et al,. Amino-substituted amphiphilic calixarenes: self-assembly and interactions with DNA. Langmuir 2008; 24: 8522-8526.
28. Lee RJ, Low PS,. Folate as a targeting device for proteins utilizing folate receptor-mediated endocytosis. In:, Francis GE, Delgado C, eds. Methods in Molecular Medicine: Drug Targeting, Vol. 25. Totowa, NJ: Humana Press, 2000: 69-76.
29. Storm G, et al,. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 1995; 17: 31-48.
30. Cho K, et al,. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008; 14: 1310-1316. (Pubitemid 351413909)
31. Parker D, ed. Macrocycle Synthesis: A Practical Approach. New York: Oxford University Press, 1996.
32. Jakobi RA, et al,. Long-chain alkyl ethers of p-nitro and p-aminocalixarenes. New J Chem 1996; 20: 493-501. (Pubitemid 126729939)
33. Kenis PJ, et al,. Supramolecular materials: molecular packing of tetranitrotetra propoxycalix[4]arene in highly stable films with second-order nonlinear optical properties. Chem Eur J 1998; 4: 1225-1234. (Pubitemid 28370063)
34. Sansone F, et al,. DNA condensation and cell transfection properties of guanidinium calixarenes: dependence on macrocycle lipophilicity, size, and conformation. J Am Chem Soc 2006; 128: 14528-14536. (Pubitemid 44749852)
35. Dalwadi G, et al,. Comparison of diafiltration and tangential flow filtration for purification of nanoparticle suspensions. Pharm Res 2005; 22: 2152-2162. (Pubitemid 41821595)
36. Harper E, et al,. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice. Clin Cancer Res 1999; 5: 4242-4248. (Pubitemid 30013811)
37. Gualbert J, et al,. Solid lipid nanoparticles (SLNs): preparation and properties of calix[4] resorcinarene derived systems. J Incl Phenom 2004; 48: 37-44. (Pubitemid 39023786)
38. Mu L, Feng SS,. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol®). J Control Release 2002; 80: 129-144. (Pubitemid 34273754)
39. Potineni A, et al,. Poly(ethylene oxide)-modified poly([beta]-amino ester) nanoparticles as a pH-sensitive biodegradable system for paclitaxel delivery. J Control Release 2003; 86: 223-234. (Pubitemid 36084272)
40. Kim SY, et al,. Toxic characteristics of methoxy poly(ethylene glycol)/poly([var epsilon]-caprolactone) nanospheres; in vitro and in vivo studies in the normal mice. Biomaterials 2003; 24: 55-63. (Pubitemid 35300203)
41. (R) Prescribing Information. Abraxis BioScience Incorporated; http://www.abraxane.com/docs/Abraxane-PrescribingInformation. pdf[accessed 16 April 2012].
42. Attawia MA, et al,. Regional drug delivery with radiation for the treatment of Ewing's sarcoma: in vitro development of a taxol release system. J Control Release 2001; 71: 193-202. (Pubitemid 32234380)
43. Huang X, Brazel CS,. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J Control Release 2001; 73: 121-136. (Pubitemid 32539245)
44. Ishida O, et al,. Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice. Int J Pharm 1999; 190: 49-56. (Pubitemid 29467471)
45. Lalor R, et al,. Cellular uptake of a fluorescent calix[4]arene derivative. J Am Chem Soc 2008; 130: 2892-2893. (Pubitemid 351455933)